Rituximab With Involved Field Irradiation for Early-stage Nodal Follicular Lymphoma: Results of the MIR Study. Issue 6 (December 2018)

• Record Type: Journal Article
• Authors: Herfarth, Klaus; Borchmann, Peter; Schnaidt, Sven; Hohloch, Karin; Budach, Volker; Engelhard, Marianne; Viardot, Andreas; Engenhart-Cabillic, Rita; Keller, Ulrich; Reinartz, Gabriele; Eich, Hans-Theodor; Witzens-Harig, Mathias; Hess, Clemens F.; Dörken, Bernd; Dürig, Jan; Wiegel, Thomas; Hiddemann, Wolfgang; Hoster, Eva; Pott, Christiane; Dreyling, Martin
• Is Part Of: HemaSphere. Volume 2:Issue 6(2018)
• Publication Date: 2018-12
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/HS9.0000000000000160
• Languages: English
• ISSNs: 2572-9241

Abstract

Abstract : Abstract: The MabThera and Involved field Radiotherapy study investigated efficacy and safety of involved field (IF) radiotherapy in combination with the anti-CD20 antibody Rituximab for early-stage follicular lymphoma (FL) in a prospective, single-arm multicenter phase 2 design. Eighty-five stage I–II FL patients received 8 cycles of Rituximab (375 mg/m 2 ) and IF irradiation (30/40 Gy). The primary endpoint was progression-free survival (PFS) 2 years from treatment start. Secondary endpoints were overall survival (OS), complete response rates, toxicity, quality of life, and minimal residual disease (MRD) response with protocol defined visits up to month 30. For the primary endpoint, PFS at 2 years was 85% for the intention-to-treat set. Long-term data were captured in selected sites and evaluated as post hoc analysis in the per protocol (PP) set: PFS and OS were 78% and 96% at 5 years with a median follow-up of 66 or 78 months, respectively. There were 17/76 recurrences in the PP set, of which 14 were outside the radiation volume only. MRD analyses revealed a clonal marker in 36% of patients at diagnosis. All but 1 marker positive patients experienced a molecular treatment response. There were 13 serious adverse events (4 related to the therapy) during the first 30 months. IF radiotherapy combined with Rituximab is well tolerated and highly efficient with low rates of recurrence in the first years in early-stage FL. The efficacy is comparable with more aggressive therapy approaches without compromising the quality of life and maintains for an extended follow-up of more than 5 years. Abstract : Supplemental Digital Content is available in the text